Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of CKD-393 in Healthy Volunteers
NCT05274880Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone, sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration at 48 hours and Maximum observed plasma concentration at 48 hours. Started Jun 2022; status: completed.
02
Drugs
lobeglitazonesitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05274880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05274880.